CARESS Study: Cabergoline for the Reduction of Endometriosis Symptoms and Lesion Size
Key facts
- Where
- Madrid, SpanyolországSee the site
- Phase
- 4. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Spanyolország
- Hospital Clínico San CarlosMadrid, SpanyolországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospital Clinico San Carlos
- Trial code
- EU 2025-522812-18-00
- Record updated
- 2025. szeptember 17.
- Original description
To evaluate the efficacy of cabergoline (0.5 mg twice weekly) in reducing the size of endometriotic lesions and alleviating pelvic pain in women with confirmed endometriosis, compared with a control group receiving standard treatment (dienogest or combined contraceptives) for endometriosis.Read full original descriptionShow less
To evaluate the efficacy of cabergoline (0.5 mg twice weekly) in reducing the size of endometriotic lesions and alleviating pelvic pain in women with confirmed endometriosis, compared with a control group receiving standard treatment (dienogest or combined contraceptives) for endometriosis.
Inclusion: Aged between 18 and 40 years old, and premenopausal; Confirmed diagnosis of endometriosis by ultrasound/magnetic resonance imaging/laparoscopy; Pelvic pain (≥1 month) assessed using a VAS scale ≥3 points; No treatment with cabergoline in the three months prior to the start of the study; BMI between 18 and 35 kg/m²; No allergy to the treatments; Consent to participate in the study; Ability to speak and understand the message.
Exclusion: Documented allergy to dopamine agonists or previous serious side effects with cabergoline; Active thromboembolic disease; History of heart valve disorders, history of fibrotic disorders, or impaired liver function; Breast Cancer; Severe uncontrolled comorbidities (ASA> III); Pregnancy or breastfeeding at the start of the study; Patient unwillingness to participate in the study.